Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB1 | P15086 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9941794 | 1.00 | CPB1 (0.58) | CPB1ALDH1A1GAACA1CA2 | |
| SCHEMBL1756902 | 1.00 | CPB1 (0.58) | CPB1ALDH1A1GAACA1CA2 | |
| SCHEMBL26666261 | 1.00 | CPB1 (0.58) | CPB1ALDH1A1GAACA1CA2 | |
| SCHEMBL1756904 | 1.00 | CPB1 (0.58) | CPB1ALDH1A1GAACA1CA2 | |
| SCHEMBL16199073 | 1.00 | CPB1 (0.58) | CPB1ALDH1A1GAACA1CA2 | |
| SCHEMBL16199089 | 0.95 | CPB1 (0.56) | CPB1ALDH1A1GAACA1CA2 | |
| SCHEMBL16199397 | 0.95 | CPB1 (0.56) | CPB1ALDH1A1GAACA1CA2 | |
| SCHEMBL6127603 | 0.95 | CPB1 (0.56) | CPB1ALDH1A1GAACA1CA2 | |
| SCHEMBL24233326 | 0.91 | CA1 (0.52) | CPB1ALDH1A1GAACA1CA2 | |
| SCHEMBL19387895 | 0.91 | CA1 (0.52) | CPB1ALDH1A1GAACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2858984-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | Vertex Pharmaceuticals Inc. (US) | 2015-04-15 | — | — | EP | disclosed |
| US-8871774-B2 | Inhibitors of influenza viruses replication | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-10-28 | — | — | US | disclosed |
| US-20140005197-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-02 | — | — | US | disclosed |
| US-20140005192-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-02 | — | — | US | disclosed |
| US-20130345218-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICALS INCORPORATED | 2013-12-26 | — | — | US | disclosed |
| WO-2013184985-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-12-12 | — | — | WO | disclosed |
| EP-2651940-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | Vertex Pharmaceuticals Incorporated (US) | 2013-10-23 | — | — | EP | disclosed |
| EP-2651938-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | Vertex Pharmaceuticals Incorporated (US) | 2013-10-23 | — | — | EP | disclosed |
| WO-2012083122-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012083117-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140005192-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | ACE, RNASEH1, ACE2 | CPB1 909/4885ALDH1A1 3087/4885GAA 500/4885 |
| US-20130345218-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | ACE, RNASEH1, ACE2 | CPB1 909/4885ALDH1A1 3087/4885GAA 500/4885 |
| US-20140005197-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | ACE, RNASEH1, ACE2 | CPB1 909/4885ALDH1A1 3087/4885GAA 500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.